These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 25344912)
1. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Li B; Li J; Xu WW; Guan XY; Qin YR; Zhang LY; Law S; Tsao SW; Cheung AL Oncotarget; 2014 Nov; 5(22):11576-87. PubMed ID: 25344912 [TBL] [Abstract][Full Text] [Related]
2. HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo. Xi R; Pan S; Chen X; Hui B; Zhang L; Fu S; Li X; Zhang X; Gong T; Guo J; Zhang X; Che S Oncotarget; 2016 Aug; 7(35):57050-57065. PubMed ID: 27489353 [TBL] [Abstract][Full Text] [Related]
3. Targeting PI3K/Akt/HSP90 signaling sensitizes gastric cancer cells to deoxycholate-induced apoptosis. Redlak MJ; Miller TA Dig Dis Sci; 2011 Feb; 56(2):323-9. PubMed ID: 20585984 [TBL] [Abstract][Full Text] [Related]
4. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy. Li B; Xu WW; Lam AKY; Wang Y; Hu HF; Guan XY; Qin YR; Saremi N; Tsao SW; He QY; Cheung ALM Oncotarget; 2017 Jun; 8(24):38755-38766. PubMed ID: 28418888 [TBL] [Abstract][Full Text] [Related]
5. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Li B; Cheung PY; Wang X; Tsao SW; Ling MT; Wong YC; Cheung AL Carcinogenesis; 2007 Nov; 28(11):2313-20. PubMed ID: 17638919 [TBL] [Abstract][Full Text] [Related]
6. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Zhang B; Zhang B; Chen X; Bae S; Singh K; Washington MK; Datta PK Br J Cancer; 2014 Feb; 110(4):946-57. PubMed ID: 24384683 [TBL] [Abstract][Full Text] [Related]
7. RUNX2 Plays An Oncogenic Role in Esophageal Carcinoma by Activating the PI3K/AKT and ERK Signaling Pathways. Lu H; Jiang T; Ren K; Li ZL; Ren J; Wu G; Han X Cell Physiol Biochem; 2018; 49(1):217-225. PubMed ID: 30138923 [TBL] [Abstract][Full Text] [Related]
8. Oridonin-induced mitochondria-dependent apoptosis in esophageal cancer cells by inhibiting PI3K/AKT/mTOR and Ras/Raf pathways. Jiang JH; Pi J; Jin H; Cai JY J Cell Biochem; 2019 Mar; 120(3):3736-3746. PubMed ID: 30229997 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma. Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438 [TBL] [Abstract][Full Text] [Related]
10. TCF21 inhibits proliferation and chemoresistance through the AKT pathway in human gastric cancer. Yang Z; Jiang X; Li D; Dong Q; Zhao H; Jiang X Gene; 2019 Jan; 682():42-49. PubMed ID: 30296564 [TBL] [Abstract][Full Text] [Related]
11. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179 [TBL] [Abstract][Full Text] [Related]
12. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865 [TBL] [Abstract][Full Text] [Related]
13. Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo. Luo XM; Xu B; Zhou ML; Bao YY; Zhou SH; Fan J; Lu ZJ PLoS One; 2015; 10(11):e0143306. PubMed ID: 26600164 [TBL] [Abstract][Full Text] [Related]
14. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736 [TBL] [Abstract][Full Text] [Related]
15. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819 [TBL] [Abstract][Full Text] [Related]
16. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma. Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206 [TBL] [Abstract][Full Text] [Related]
17. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772 [TBL] [Abstract][Full Text] [Related]
18. Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Zhang B; Leng C; Wu C; Zhang Z; Dou L; Luo X; Zhang B; Chen X Oncol Rep; 2016 Mar; 35(3):1807-15. PubMed ID: 26647806 [TBL] [Abstract][Full Text] [Related]
19. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779 [TBL] [Abstract][Full Text] [Related]
20. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Li B; Tsao SW; Li YY; Wang X; Ling MT; Wong YC; He QY; Cheung AL Int J Cancer; 2009 Dec; 125(11):2576-85. PubMed ID: 19551863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]